Sign in →

Test ID: MAMLF MAML2 (11q21) Rearrangement, Mucoepidermoid Carcinoma (MEC), FISH, Tissue

Useful For

Supporting a diagnosis of mucoepidermoid carcinoma

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
_PBCT Probe, +2 No, (Bill Only) No
_PADD Probe, +1 No, (Bill Only) No
_PB02 Probe, +2 No, (Bill Only) No
_PB03 Probe, +3 No, (Bill Only) No
_IL25 Interphases, <25 No, (Bill Only) No
_I099 Interphases, 25-99 No, (Bill Only) No
_I300 Interphases, >=100 No, (Bill Only) No

Testing Algorithm

This test does not include a pathology consultation. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge. 


This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.


Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

Method Name

Fluorescence In Situ Hybridization (FISH)

Reporting Name

MAML2 (11q21), FISH, Ts

Specimen Type


Necessary Information

Provide a reason for referral and pathology report with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.

Specimen Required

Submit only 1 of the following specimens:


Specimen Type: Tissue

Preferred: Tissue block

Container/Tube: Formalin-fixed, paraffin-embedded (FFPE) tumor tissue block.

Collection Instructions: Blocks prepared with alternative fixation methods may be acceptable; provide fixation method used.


Acceptable: Slides

Specimen Volume: Four consecutive, unstained, 5 micron-thick sections placed on positively charged slides and 1 hematoxylin and eosin-stained slide.

Specimen Minimum Volume

Two consecutive, unstained, 5-micron-thick sections placed on positively charged slides, and 1 hematoxylin and eosin-stained slide.

Specimen Stability Information

Specimen Type Temperature Time
Tissue Ambient (preferred)

Clinical Information

Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland neoplasm, representing over 30% of all malignant salivary gland tumors. The diagnosis of MEC can be quite challenging due to the degree of histologic overlap with other glandular, clear cell, or oncocytic salivary gland tumors. MAML2 rearrangements are detectable in 80% to 85% of MEC, but not in morphologic mimics such as oncocytic cystadenoma, Warthin tumor, oncocytoma, oncocytic carcinoma, acinic cell carcinoma, and metastatic renal cell carcinoma.

Reference Values

An interpretive report will be provided.


A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal cutoff for the MAML2 probe.


A positive result is consistent with a diagnosis of mucoepidermoid carcinoma (MEC).


A negative result suggests no rearrangement of the MAML2 gene region at 11q21. However, this result does not exclude the diagnosis of MEC.

Clinical Reference

1. Stewart FW, Foote FW, Becker WF: Mucoepidermoid tumors of salivary glands. Ann Surg 1945;122:820-844

2. Spiro RH, Huvos AG, Berk R, Strong EW: Mucoepidermoid carcinoma of salivary gland origin. A clinicopathologic study of 367 cases. Am J Surg 1978;136:461-468

3. Seethala RR, Dacic S, Cieply K, et al: A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol 2010 Aug;34(8):1106-1121

4. Behboudi A, Enlund F, Winnes M, et al: Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer 2006 May;45(5):470-481

Day(s) and Time(s) Performed

Samples processed Monday through Sunday. Results reported Monday through Friday, 8 a.m.5 p.m. CST.

Analytic Time

7 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

88271x2, 88291 – DNA probe, each (first probe set), Interpretation and report

88271x2 – DNA probe, each; each additional probe set (if appropriate)

88271x1 – DNA probe, each; coverage for sets containing 3 probes (if appropriate)

88271x2 – DNA probe, each; coverage for sets containing 4 probes (if appropriate)

88271x3 – DNA probe, each; coverage for sets containing 5 probes (if appropriate)

88274 w/modifier 52 – Interphase in situ hybridization, <25 cells, each probe set (if appropriate)

88274 – Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)     

88275 – Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MAMLF MAML2 (11q21), FISH, Ts In Process


Result ID Test Result Name Result LOINC Value
54689 Result Summary 50397-9
54692 Interpretation 69965-2
54691 Result 62356-1
CG930 Reason For Referral 42349-1
54918 Specimen 31208-2
54694 Source 31208-2
54695 Tissue ID 80398-1
55136 Method 49549-9
55137 Additional Information 48767-8
53394 Disclaimer 62364-5
54696 Released By 18771-6
Mayo Clinic Laboratories | Oncology Catalog Additional Information: